Citation & Authors
Endocr Pract. 2026;32(9):1378–1386.
ABSTRACT · RESEARCH SUMMARY
Research summary
After TriNetX matching, each group contained 20,735 patients with osteoporosis. Compared with denosumab, intravenous bisphosphonates were associated with lower risks of incident type 2 diabetes at 1, 3, 5, and 7 years; the 5-year HR was 0.818 (95% CI 0.747–0.895). The direction favors intravenous bisphosphonates; it should not be misreported as a lower diabetes risk with denosumab.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
Key findings
After matching, each group included 20,735 patients. Compared with denosumab, intravenous bisphosphonates were associated with a lower risk of incident type 2 diabetes: the 5-year HR was 0.818 (95% CI 0.747–0.895), and the 7-year HR was 0.821 (95% CI 0.753–0.896).
The study compares associations between two treatment strategies; it does not establish that denosumab causes diabetes. Prospective validation is needed.
